Background {#Sec1}
==========

Venous thromboembolism (VTE), defined as deep vein thrombosis (DVT) or pulmonary embolism (PE), is a common, potentially fatal, yet treatable condition. Anticoagulation is the mainstay of VTE treatment and is divided into three phases: the initial phase (first 5 to 10 days after diagnosis), the long-term phase (from the initial phase to 3--6 months), and the extended phase (beyond 3--6 months) \[[@CR1]\]. Anticoagulant therapy for at least 3 months is recommended in all patients with acute VTE \[[@CR1]\]. Thereafter, balancing the long-term risk of recurrent VTE, defined by etiology of the VTE and the presence of persistent risk factors, against the long-term risk of major bleeding from anticoagulation informs treatment duration. Etiology of VTE is defined as provoked or unprovoked \[[@CR2]\]. Patients with an unprovoked event have a high risk of recurrent VTE after discontinuation of anticoagulation (10% after 1 year, 36% after 10 years) \[[@CR3]\]. Therefore, the 2016 American College of Chest Physicians and the 2014 European Society of Cardiology guidelines both suggest indefinite anticoagulation in patients with unprovoked VTE, unless they have a high risk of bleeding \[[@CR1], [@CR4]\].

A previous meta-analysis by Linkins and colleagues \[[@CR5]\] reported a major bleeding rate of approximately 3% per year during extended anticoagulation. However, the analysis was based on a heterogeneous population of VTE patients (i.e., mix of provoked and unprovoked VTE), and the duration of extended anticoagulation in most included studies was limited to 3 months (i.e., 6 months of total treatment duration). To inform the decision on whether patients with a first unprovoked VTE should continue anticoagulation indefinitely, understanding the *long-term* risk of major bleeding on extended anticoagulation is crucial.

Since the publication of the meta-analysis by Linkins et al. in 2003, numerous prospective studies involving patients with a first unprovoked VTE have reported on the risk of major bleeding during extended anticoagulation with patient follow-up lasting beyond 3 months and up to a maximum follow-up of 4 years \[[@CR6]\]. This provides the opportunity to summarize and establish reliable and precise estimates of the *long-term* risk of major bleeding on extended oral anticoagulant therapy in patients with first unprovoked VTE.

Objective {#Sec2}
=========

The aim of this systematic review and meta-analysis is to quantify the rate of major bleeding events during extended oral anticoagulation in patients with a first unprovoked VTE, who have completed at least 3 months of initial treatment.

Methods {#Sec3}
=======

This protocol was developed following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement \[[@CR7]\] and is registered in the PROSPERO international register of prospective systematic review database (CRD42019128597). Any modifications made to the study methods during conduct of the review will be reported and justified in the publication of the final report. The final publication will be reported according to guidance from the PRISMA statement \[[@CR8]\].

Eligibility criteria {#Sec4}
--------------------

Studies meeting the following criteria will be included in the systematic review.

### Population {#Sec5}

The targeted group of participants will be adults with a first episode of objectively confirmed, symptomatic major VTE (proximal DVT or PE) that is either unprovoked or provoked by minor transient risk factors, according to the International Society on Thrombosis and Hemostasis (ISTH) definition \[[@CR2]\]. Patients will be eligible if they have received treatment with an approved oral anticoagulant therapy, continued for a minimum of six additional months beyond completion of at least 3 months of anticoagulation with either (1) intravenous heparin or low molecular weight heparin (LMWH) for 3 months, or (2) intravenous heparin or LMWH for at least 5 days followed by dabigatran, edoxaban, or a vitamin K antagonist, or (3) apixaban or rivaroxaban. Studies will be excluded if they only include patients with VTE associated with major transient and/or persistent provoking risk factors according to the ISTH definition \[[@CR2]\].

### Interventions and comparators {#Sec6}

The review will include studies wherein participants have received treatment with an approved oral anticoagulant therapy, continued for a minimum of six additional months beyond completion of at least 3 months of anticoagulation. As the study objective is to establish the rate of major bleeding during extended anticoagulation, a comparator is not applicable. As such, all studies, including each arm of a randomized controlled trial (RCT), will be evaluated as an independent observational cohort, with follow-up starting at the time that oral anticoagulants are continued for secondary prevention (i.e., beyond completion of at least 3 months of *initial* treatment).

### Outcome {#Sec7}

The primary outcome will be the rate of major bleeding (as defined by the ISTH \[[@CR9]\] or by individual studies) on extended oral anticoagulation.

### Study design {#Sec8}

Studies eligible for this systematic review will consist of both RCTs and prospective cohort studies. Case reports, case series, case-control, or cross-sectional studies, as well as retrospective cohort and registry-based studies, will be excluded.

Search strategy {#Sec9}
---------------

In conjunction with an information specialist, electronic databases including MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials will be systematically searched (from inception to March 01, 2019) with no language restrictions. Search terms will be related to VTE, major bleeding, anticoagulants, and study design. We will use medical subject heading (MeSH) terms. We will supplement our search with keywords and adjust vocabulary and syntax across databases. The search strategy for EMBASE and MEDLINE was reviewed by an information specialist and is presented in Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}, respectively. Reference lists of retrieved articles will be hand-searched to identify additional relevant studies, while gray literature will not be considered. Table 1EMBASE search strategyNo.Searches1Venous Thrombosis/2(ven\* adj2 thrombos\*).ti, ab.3Deep Vein Thrombosis/4(deep adj3 thrombos\*).ti, ab.5Pulmonary Embolism/6(pulmonary adj2 embolism\*).ti, ab.7Venous Thromboembolism/8(ven\* adj2 thromboembolism\*).ti, ab.9Recurrent Venous Thromboembolism/101 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 911secondary prevention/12secondary prevention\*.ti, ab.13(relapse adj2 prevention\*).ti, ab.14(extended adj2 therap\*).ti, ab.1511 or 12 or 13 or 1416Hemorrhage/17(hemorrhag\* or haemorrhag\*).ti, ab.1816 or 1719Anticoagulants/20Antithrombins/21(anticoagulant\* or anti-coagulant\* or antithrombin\* or anti-thrombin\*).tw.22(thrombin adj3 inhibit\*).tw.23(Factor Xa adj2 (antagonist? or inhibit\* or block\*)).tw.24heparin/ or exp heparin, low-molecular-weight/25(heparin\* or beparine or clarin or contusol or disebrin or eleparon or elheparin or elheparon or epiheparin or gag 98 or helberina or hepaflex or hepalean or heparitin\* or hepcon or hepsal or inhepar or inviclot or lipo-hepin or lipohepin or liquemin or liquemine or menaven or monoparin or mucoitin or multiparin or nevparin or noparin or panheparin or panhepin or panheprin or parinix or praecivenin or pularin or thromb\*or niparin or vetren or vaster).tw.26liquaemin.tw.27dalteparin\*.tw.28fragmin\*.tw.29enoxaparin\*.tw.30clexane.tw.31lovenox.tw.32fraxiparin\*.tw.33nadroparin\*.tw.34Warfarin/35(warfarin or warfant or tedicumar or savaysa or endoxaban or befarin or adoisine or carfin or circuvit or coumadan or coumafene or coumaphene or dagonal or tintorane or uniwarfin or waran or warfar or warnerin or farin or jantoven or kumatox or maforan or orfarin or panwarfarin or panwarfin or prothromadin or warfil\* or sofarin).tw.36coumadin\*.tw.37aldocumar.tw.38marevan.tw.39(Vitamin K adj2 (antagonist? or inhibit\* or block\*)).tw.4019 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 3941(random\$ or placebo\$ or single blind\$ or double blind\$ or triple blind\$).ti, ab.42RETRACTED ARTICLE/43or/41-4244(animal\$ not human\$).sh,hw.45(book or conference paper or editorial or letter or review).pt. not exp. randomized controlled trial/46(random sampl\$ or random digit\$ or random effect\$ or random survey or random regression).ti, ab. not exp. randomized controlled trial/4743 not (44 or 45 or 46)48exp cohort analysis/49exp longitudinal study/50exp prospective study/51exp follow up/52cohort\$.tw.53or/48--525447 or 535510 and 15 and 18 and 40 and 545610 and 18 and 40 and 54 Table 2MEDLINE search strategyNo.Searches1exp Venous Thrombosis/2(ven\* adj2 thrombos\*).ti, ab.3exp Deep Vein Thrombosis/4(deep adj3 thrombos\*).ti, ab.5exp Pulmonary Embolism/6(pulmonary adj2 embolism\*).ti, ab.7Venous Thromboembolism/8(ven\* adj2 thromboembolism\*).ti, ab.9Recurrent Venous Thromboembolism/101 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 911secondary prevention/12secondary prevention\*.ti, ab.13(relapse adj2 prevention\*).ti, ab.14(extended adj2 therap\*).ti, ab.1511 or 12 or 13 or 1416exp Hemorrhage/17(hemorrhag\* or haemorrhag\*).ti, ab.1816 or 1719Anticoagulants/20Antithrombins/21(anticoagulant\* or anti-coagulant\* or antithrombin\* or anti-thrombin\*).tw.22(thrombin adj3 inhibit\*).tw.23(Factor Xa adj2 (antagonist? or inhibit\* or block\*)).tw.24heparin/ or exp. heparin, low-molecular-weight/25(heparin\* or beparine or clarin or contusol or disebrin or eleparon or elheparin or elheparon or epiheparin or gag 98 or helberina or hepaflex or hepalean or heparitin\* or hepcon or hepsal or inhepar or inviclot or lipo-hepin or lipohepin or liquemin or liquemine or menaven or monoparin or mucoitin or multiparin or nevparin or noparin or panheparin or panhepin or panheprin or parinix or praecivenin or pularin or thromb\*or niparin or vetren or vaster).tw.26liquaemin.tw.27dalteparin\*.tw.28fragmin\*.tw.29enoxaparin\*.tw.30clexane.tw.31lovenox.tw.32fraxiparin\*.tw.33nadroparin\*.tw.34Warfarin/35(warfarin or warfant or tedicumar or savaysa or endoxaban or befarin or adoisine or carfin or circuvit or coumadan or coumafene or coumaphene or dagonal or tintorane or uniwarfin or waran or warfar or warnerin or farin or jantoven or kumatox or maforan or orfarin or panwarfarin or panwarfin or prothromadin or warfil\* or sofarin).tw.36coumadin\*.tw.37aldocumar.tw.38marevan.tw.39(Vitamin K adj2 (antagonist? or inhibit\* or block\*)).tw.4019 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 3941randomized controlled trial.pt.42controlled clinical trial.pt.43random allocation.sh.44double-blind method.sh.45single-blind method.sh.4641 or 42 or 43 or 44 or 4547clinical trial.pt.48(clin\$ adj25 trial\$).ti, ab.49(singl\$ or doubl\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).ti, ab.50placebos.sh.51placebo\$.ti, ab.52random\$.ti, ab.53research design.sh.54exp cohort studies/55cohort\$.tw.56controlled clinical trial.pt.57epidemiologic methods/5848 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 575946 or 586010 and 15 and 18 and 40 and 596110 and 18 and 40 and 59

Data management and selection process {#Sec10}
-------------------------------------

Results from the literature search will be uploaded to Covidence \[[@CR10]\]. Screening of titles/abstracts as well as full-text articles will be performed by at least two independent investigators of the review team. Discrepancies will be resolved by consensus discussion or by a third person if needed. The process of study selection will be presented using the PRISMA flow diagram \[[@CR8]\]. In the case of published reports including duplicate patients, only the publication with the longest follow-up of patients will be included.

Data collection {#Sec11}
---------------

Data from included studies will be collected using a standardized data extraction form. Data extraction will be conducted by at least two reviewers independently, with clarifications requested from the study's authors when necessary. A third person will verify a subset of the studies to ensure accurate data collection. The standardized data extraction form will be piloted by two reviewers independently for the first five full-text articles. After comparing the results of the pilot phase for data extraction, further changes will be made to the standardized data extraction form, if needed. Disagreements between reviewers will be resolved by consensus or by a third person if required.

We will collect the following information from included studies: Study information: year of study publication, author, and journal informationStudy characteristics: design, period, country(ies), funding source, and criteria used to define VTE and its etiology.Participant characteristics: number of eligible patients, number of eligible male patients, mean age, site of initial VTE, type and dose of anticoagulant used during the initial treatment period, person-years of follow-up, and number of patients lost to follow-up.Intervention characteristics: type and dose of anticoagulant agent used during the extended treatment period.Outcomes: major, clinically relevant non-major, intracranial, and fatal bleeding (as defined by the ISTH or by individual studies), as well as recurrent VTE and recurrent fatal PE. Each study's chosen definition of bleeding outcomes will be rigorously documented.

Outcomes and prioritization {#Sec12}
---------------------------

The primary outcome will be the rate of major bleeding during extended oral anticoagulation. Major bleeding is a patient-relevant outcome and the primary safety outcome of all recent phase III anticoagulation trials \[[@CR11]\]. Secondary outcomes will include the rate of clinically relevant non-major bleeding, intracranial bleeding, fatal bleeding, recurrent VTE, and fatal recurrent PE during extended oral anticoagulation. We will also calculate the case-fatality rate of major bleeding and recurrent VTE during extending anticoagulation, from the total number of fatal (bleeding and recurrent PE events) divided by the total number of major bleeding and recurrent VTE events, respectively. Bleeding outcomes will be defined as per ISTH definition \[[@CR9]\] for the primary analysis, and secondary analysis will include bleeding outcomes as defined by the individual studies. These secondary outcomes were chosen because of their clinical relevance and importance in assessing the net clinical benefit of extended anticoagulation.

Risk of bias assessment {#Sec13}
-----------------------

At least two reviewers will independently assess the risk of bias at the individual study level. For a subset of studies, a third reviewer will verify the accuracy of the risk of bias assessment done by the first two reviewers. Conflicts will be resolved by consensus or by a third reviewer if needed. Given each arm of a RCT will be evaluated as an independent observational cohort, the risk of bias for each study will be assessed using the Newcastle-Ottawa scale for prospective cohort studies \[[@CR12]\].

Data synthesis {#Sec14}
--------------

The rate (expressed as events per 100 person-years) of the primary and secondary outcomes will be calculated from each observational cohort from the number of events and person-years of follow-up. If feasible from the available data, these rates will be calculated and reported at standardized time intervals during extended anticoagulation (i.e., at 6, 12, 18, 24, 36, 48, 60, and 120 months following completion of the *initial* 3- to 6-month period of anticoagulation) to account for the different length of follow-up from each study. To assess clinical and statistical heterogeneity, we will compare study design, patients' characteristics, and studied interventions of included studies prior to pooling results. Statistical heterogeneity will be measured using Cochrane's Q (statistically significant at *p* \< 0.10) and the *I*^2^ statistic (\> 75% considered to represent high heterogeneity).

If pooling is deemed appropriate, we will combine the total number of major bleeding events and person-years of follow-up across all included study cohorts to calculate a weighted estimate of the absolute rate of major bleeding per 100 person-years of follow-up. If and when possible, this pooled rate will be calculated for each of the standardized time periods defined above. Furthermore, the cumulative incidence of major bleeding events at each of the standardized time intervals will be estimated from the absolute rate of major bleeding events at each time period, if feasible from the available data. These analyses will be repeated for all secondary outcomes. A random effect model will be used for data synthesis due to the expected diversity of the studied interventions.

All meta-analyses will be performed using StatsDirect version 3 (Cheshire, UK) software \[[@CR13]\].

### Planned sensitivity analyses {#Sec15}

Sensitivity analyses will be undertaken to establish the robustness of primary findings. We will perform the following sensitivity analyses excluding study cohorts whose event rates are outliers, as well as excluding studies judged to be at high risk of bias. Estimates from overall and sensitivity analyses will be compared to gauge the impact of potential heterogeneity and biases on the primary results.

### Planned subgroup analyses {#Sec16}

If feasible from the available data, subgroup analyses will be performed based on the study design (i.e., cohorts derived from randomized trials versus prospective observational studies), type of anticoagulation used for extended treatment, and patient characteristics. Several patient characteristics of interest were previously shown to be associated with bleeding in VTE patients receiving anticoagulation or used to define risk of recurrent VTE and case fatality in this patient population. Accordingly, we will include the following characteristics: sex \[[@CR14]--[@CR19]\], age (less than 65 years old and 65 years old or over) \[[@CR1], [@CR20]--[@CR22]\], prior major bleeding \[[@CR1], [@CR20]--[@CR26]\], concomitant use of anti-platelet therapy \[[@CR1], [@CR20]\], anemia (i.e., hemoglobin less than 90, 100, 110, 120, and 130 g/L) \[[@CR23]--[@CR27]\], creatinine clearance less than 30, 50, and 60 mL/min \[[@CR1], [@CR28]\], and site of initial VTE event (i.e., isolated proximal DVT, isolated PE, or DVT and PE) \[[@CR29]\]. Findings from all analyses will be presented in the final report.

Meta-bias assessment {#Sec17}
--------------------

Meta-bias will be assessed through the use of funnel plots to evaluate potential reporting bias if applicable. Additionally, we will compare a random effect estimates to fixed effect estimates to evaluate whether small sample bias is present. Finally, selective outcome reporting will be assessed by comparing the reported outcome from the included studies to their published protocol, where available.

Discussion {#Sec18}
==========

In this systematic review and meta-analysis, we aim to provide reliable estimates regarding the risk of major bleeding events at clinically relevant time points during extended anticoagulation in patients with a first unprovoked VTE. This knowledge will inform clinical practice guidelines, and help clinicians and patients balance the risks and benefits of anticoagulation to guide treatment duration.

DVT

:   Deep vein thrombosis

ISTH

:   International Society on Thrombosis and Hemostasis

LMWH

:   Low molecular weight heparin

PE

:   Pulmonary embolism

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-analysis

PRISMA-P

:   Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols

RCT

:   Randomized controlled trial

VTE

:   Venous thromboembolism
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